Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283437 | 0.83 | MGAM (0.57) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL731664 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL733088 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TSHR | |
| SCHEMBL5785545 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL5968591 | 0.78 | EGLN1 (0.39) | ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL8909532 | 0.77 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL1820175 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1972716 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL942008 | 0.76 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL1768486 | 0.76 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527186-A4 | — | UNIV ILLINOIS (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0527186-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | The Board of Trustees for the University of Illinois (US) | 1993-02-17 | — | — | EP | claimed |
| WO-1991016820-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1991-11-14 | — | — | WO | claimed |
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3800192-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-04-07 | — | — | EP | disclosed |
| US-10935544-B2 | Glycan arrays and method of use | OBI PHARMA, INC. (TW) | 2021-03-02 | — | — | US | disclosed |
| EP-3265109-B1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-10-21 | — | — | EP | disclosed |
| US-20200308221-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-10-01 | — | — | US | disclosed |
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-04-28 | — | — | US | disclosed |
| EP-3344806-A1 | GLYCAN ARRAYS AND METHOD OF USE | OBI Pharma, Inc. (TW) | 2018-07-11 | — | — | EP | disclosed |
| US-20030099945-A1 | Parallel selex | INVENUX, INC. (US) | 2003-05-29 | — | — | US | disclosed |
| EP-1115887-A4 | PARALLEL SELEX | INVENUX INC (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020045679-A1 | Aqueous ink composition | HITACHI MAXELL, LTD. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1115887-A1 | PARALLEL SELEX | Invenux, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6048698-A | PRODUCING PRODUCTS BY BOND FORMATION OF A REACTANT BOUND TO NUCLEIC ACID AND A FREE REACTANT, THEN CONTACTING PRODUCT LIBRARY WITH TARGET TO PARTITION PRODUCTS BY ABILITY TO PERFORM PRESELECTED FUNCTION | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-2000017398-A1 | PARALLEL SELEX | INVENUX, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5858660-A | FORMING PRODUCT LIBRARY BY CONTACTING TWO OR MORE REACTANTS WHERE ONE REACTANT IS COUPLED TO NUCLEIC ACID CAPABLE OF MEDIATING BOND FORMATION, SELECTING PRODUCTS HAVING PREDETERMINED CHARACTERISTICS | NEXSTAR PHARMACEUTICLAS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5244762-A | Polymers of hydroxyacrylic amides and hydroxyacrylic esters, hydroxy group modified to become ether, ester, sulfonate, carbamate | XEROX CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
| US-5242892-A | With 5-aminolevulinic acid | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1993-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633415-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | MGAM 1502/4885GAA 1903/4885SI 382/4885 |
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | MGAM 1502/4885GAA 1903/4885SI 382/4885 |
| US-20030099945-A1 | Parallel selex | SELE, MTREX, NSUN3 | MGAM 1248/4885GAA 2607/4885SI 1650/4885 |
| US-20200308221-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | MGAM 1502/4885GAA 1903/4885SI 382/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | MGAM 1502/4885GAA 1903/4885SI 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.